HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China

The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited's HCM amdizalisib (HMPL-689).
The selective and potent PI3Kδ inhibitor is being developed for relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin's lymphoma (NHL).
Updated preliminary results from the ongoing Phase Ib expansion study in China will be presented as a Proffered Paper at the 2021 ESMO (European Society for Medical Oncology) Congress on September 20.
Related content: Benzinga's Full FDA Calendar.
Price Action: HCM stock is up 3.17% at $40.08 during the premarket session on the last check Monday.

Momentum54.90

Growth68.34

QualityNot Available

Value4.30

Short

Medium

Long